Real-world experience with antivirus for the treatment of COVID-19


  • Sutharot Parinyapoonno -


COVID-19 antiviral drug, molnupiravir, farvipiravir, coronavirus 2019


Background: The use of oral antivirals plays an important role in controlling the severity and spread of the novel coronavirus 2019.

Objective: To evaluate the treatment effect and safety of oral antivirals used at Hua Hin Hospital.

Method: A retrospective study was conducted from the medical records of COVID-19 patients receiving oral antiviral therapy. Between April and July 2022, when molnupiravir was introduced and used for the first time in Thailand.

Results: Out of 1,014 patients with COVID-19 aged 18 and over who were not pregnant and planned to receive antiviral therapy for COVID-19, 58 received molnupiravir; 27 were outpatients and 31 were inpatients. Patients treated with favipiravir were matched based on age, gender, vaccination history, and the risk factors for severe symptoms from COVID-19 according to patients taking molnupiravir. The treatment outcomes and adverse reactions from oral antivirals were evaluated using the chi-square test and independent t-test. We found that 3.7% of the molnupiravir and 7.4% of the favipiravir outpatient groups (p =.492) were admitted to the hospital one day after home isolation treatment. The mean length of hospital stay was not different between the molnupiravir and favipiravir groups (6.35 days (SD 3.52) and 7.96 days (SD 3.96), respectively) (p = 0.78). No patient was found dead. This was not different from favipiravir patients who were 3.2% admitted to intensive care units, 6.5% received corticosteroids, and 6.5% died. Favipiravir was converted to remdesivir by 19.4%, whereas the molnupiravir group had no conversion to remdesivir (p =.024). Two mild adverse events were reported in the molnupiravir group, and no patients recurred in 28 days.

Conclusion: The use of favipiravir and molnupiravir as oral anti-coronavirus drugs for outpatients can treat COVID-19 without difference. While the use of favipiravir in hospitalized patients requiring conversion to remdesivir was higher than in the molnupiravir group, and two deaths were reported. There were no serious adverse events or recurrences at 28 days found in either patient group.


Download data is not yet available.


World Health Organization. Coronavirus disease (covid-19) pandemic. Europe: WHO; 2022.[27 June 2022].

World Health Organization. Coronavirus disease (COVID-19. WHO; 2022.[27 June 2022].

Department of Disease Control. Guidelines for vaccination against COVID-19 in the 2021 outbreak situation in Thailand, 1st Revised Edition, June 1, 2021, page 1. (in Thai)

Department of Medical Services. Guidelines for medical practice, diagnosis, treatment and prevention of hospital infections. Case of Coronavirus Disease 2019 (COVID-19), 24th revision dated 11 July 2022 for doctors and public health personnel. (in Thai)

Pannee Leelawattanachai, Tananun Tanpaibule, Favipiravir for the Treatment of Coronavirus Disease 2019.TJHP vol.31 No 2 May - Aug 2021:141-157 (in Thai)

คณิต เต็มไตรรัตน์, เฉลิมชัย ชินตระการ. COVID-19. Thai Journal of Otolaryngology Head and Neck surgery. Vol. 21 No.1: January - June 2020: (61-67) (in Thai)

National Institutes of Health.COVID-19 treatment guidelines. 2022.NIH; [27 June 2022].

Department of Medical Services. Guidelines for medical practice, diagnosis, treatment and prevention of hospital infections. Case of Coronavirus Disease 2019 (COVID-19), 21st revision dated 22 March 2022 for doctors and public health personnel. (in Thai)

National Drug System Development Committee, Royal Gazette. Announcement of the National Drug System Development Committee on the national list of essential drugs For Coronavirus Disease 2019 (COVID-19) B.E. 2565. Volume 139, Special Section 274. Page 90. 25 Nov. 2022. (in Thai)

The Food and Drug Administration. Announcement of the Food and Drug Administration on “Risk-Based Approach Safety Monitoring Program”.9 Oct.2017. (in Thai)

Ministry of Health Malaysia. Favipiravir (AVIGAN®) to Treat Coronavirus Disease 2019 (COVID-19); 2022.

The Government Pharmaceutical Organization. Favir (favipiravir) leaflet.1A 32/64 (NG). revision date Aug 2021.

อาทิตา ดิจค์สตรา. Development and studies of molnupiravir for COVID-19 treatment. Center for Continuing Pharmacy Education.No. 1011-4-000-001-01-2565. 25 Jan 2022. (in Thai)

Merk Sharp & Dohme Singapore Trading PTE.LTD. Molnatris (molnupiravia) leaflet. approve in Nov 2021.

Santi Laurini, G., Montanaro, N., & Motola, D. (2023). Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data. Journal of Clinical Medicine, 12(1), 34.

Hung, D. T., Ghula, S., Aziz, J. M. A., Makram, A. M., Tawfik, G. M., Abozaid, A. A. F., et al. The efficacy and adverse effects of favipiravir on COVID-19 patients: a systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis. 2022 Jul; 120:217-227.doi: 10.1016/j.ijid.2022.04.035. Epub 2022 Apr 22.

Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., et al. Molnupiravir for oral treatment of Covid-19 in non-hospitalized patients. New England Journal of Medicine, 386(6), 509-520.

Rattanaumpawan, P., Jirajariyavej, S., Lerdlamyong, K., Palavutitotai, N., & Saiyarin, J. (2022). Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand. Antibiotics, 11(6), 805.




How to Cite

Parinyapoonno, S. (2023). Real-world experience with antivirus for the treatment of COVID-19 . Hua Hin Medical Journal, 3(1), 75–89. Retrieved from



Original article